Trade-Off Between Lipid-Lowering Therapy and Costs in Patients With Cardiovascular Disease

Abstract

Figure. Cumulative incidence of a key endpoint for the FOURIER trial and the READ-CAD study: a composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization in the FOURIER trial and a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, unstable angina requiring emergency hospitalization, or coronary revascularization based on clinical indication in the READ-CAD study. In the FOURIER trial, low-density lipoprotein cholesterol (LDL-C) levels were approximately 30 mg/dL and 90 mg/dL in the evolocumab and placebo groups, respectively, at 3-year follow-up. 6 In the the READ-CAD study, LDL-C levels were approximately 91 mg/dL and 77 mg/dL in the pitavastatin 1-mg and 4-mg groups, respectively-at 3-year follow-up. 3